Items Tagged ‘aromasin’

April 28th, 2016

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

By

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

View full entry

Tags: aromasin, Breast Cancer, exemestane, HER2-negative, hormone-positive, News, premenopausal, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


December 19th, 2014

Study Confirms Role of Ovarian Suppression and Aromasin for Younger Women With Hormone-sensitive Breast Cancer

By

Ovarian suppression combined with the anti-estrogen drug Aromasin® (exemestane) appears to greatly reduce the risk of breast cancer recurrence in younger women according to the results of the Suppression of Ovarian Function Trial (SOFT) presented at the 2014 San Antonio Breast Cancer Symposium in Texas.[1] These results were also published online simultaneously in The New […]

View full entry

Tags: aromasin, Breast Cancer, News, ovarian suppression, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


August 19th, 2014

Aromasin is New Treatment Option for Young Women With Hormone-sensitive Breast Cancer

By

The results of a recently completed clinical study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and now published online in the New England Journal of Medicine demonstrate that Aromasin® (exemestane), is more effective than tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment […]

View full entry

Tags: aromasin, Breast Cancer, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


June 25th, 2014

Aromasin Reduces Risk of Recurrence in Early Breast Cancer

By

In a joint analysis of two clinical trials reported at the American Society of Clinical Oncologists meeting in Chicago, researchers found that premenopausal women undergoing hormone suppression and who were treated with Aromasin® (exemestane) had reduced breast cancer recurrence relative to those treated with tamoxifen. There was not, however, a difference in overall survival after […]

View full entry

Tags: aromasin, Breast Cancer, News, recurrence, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer